Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Relapsed multiple myeloma.

S Pandit1, D H Vesole

  • 1Division of Hematology/Oncology, Medical College of Wisconsin, 9200 West Wisconsin Avenue, Milwaukee, WI 53226, USA.

Current Treatment Options in Oncology
|June 12, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The high explosives & affected targets (HEAT) dataset.

Data in brief·2026
Same author

Post-tonsillectomy Hemorrhage in Patients Receiving Ketorolac Analgesic.

Kathmandu University medical journal (KUMJ)·2023
Same author

Economic burden of limited English proficiency: A prevalence-based cost of illness study of its direct, indirect, and intangible costs.

Journal of postgraduate medicine·2022
Same author

Parental-perceived health-related quality of life of school students with borderline intellectual functioning: A cross-sectional questionnaire-based study in Mumbai, Maharashtra, India.

Journal of postgraduate medicine·2022
Same author

Janeway lesion.

QJM : monthly journal of the Association of Physicians·2020
Same author

Griscelli syndrome type 2.

QJM : monthly journal of the Association of Physicians·2019
Same journal

Interaction between Regulated Cell Death Pathways and Core Cellular Processes: Unraveling the Molecular Mechanisms of Cardiotoxicity of Antitumor Drugs.

Current treatment options in oncology·2026
Same journal

Advances in Immunotherapy for Breast Cancer: Up-to-date Strategies of Immune Checkpoint Inhibitors and Therapeutic Vaccines.

Current treatment options in oncology·2026
Same journal

Recent Advances in Neoadjuvant Treatment of Anaplastic Thyroid Carcinoma: A Narrative Review.

Current treatment options in oncology·2026
Same journal

The Immunological Landscape of the Tumor Microenvironment: Implications for Immunotherapy of Unresectable and Metastatic Soft Tissue Sarcomas.

Current treatment options in oncology·2026
Same journal

Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer.

Current treatment options in oncology·2026
Same journal

Emerging Applications of CAR-T Cell Therapy in Overcoming Resistance and Expanding Targets in Hematologic Malignancies: Insights from Recent Research.

Current treatment options in oncology·2026
See all related articles

Treating relapsed multiple myeloma is difficult. Thalidomide shows promise as a single agent, but stem cell transplantation offers better long-term outcomes for eligible patients.

Area of Science:

  • Hematology
  • Oncology
  • Clinical Therapeutics

Background:

  • Relapsed multiple myeloma treatment presents significant clinical challenges.
  • Current salvage therapies offer limited response durations (6-18 months median survival).
  • No randomized trials have established a gold standard for salvage therapy.

Purpose of the Study:

  • To evaluate thalidomide as a single agent and in combination for relapsed multiple myeloma.
  • To assess the efficacy of high-dose therapy with autologous hematopoietic stem cell transplant (AHSCT).
  • To consider immune-based therapy with allogeneic hematopoietic stem cell transplant (allo-HSCT).

Main Methods:

  • Review of thalidomide efficacy (30-35% response rate at 400 mg/d).
  • Analysis of combination therapy with thalidomide and dexamethasone or chemotherapy.

Related Experiment Videos

  • Evaluation of outcomes for AHSCT and allo-HSCT in eligible patients.

    • Main Results:

    • Thalidomide monotherapy shows manageable toxicity and rapid responses, but brief durations (3-6 months).
    • High-dose therapy with AHSCT demonstrates superior response rates, duration, and survival versus historical controls.
    • Allo-HSCT is recommended for younger patients with compatible donors.

    Conclusions:

    • Thalidomide is a promising single agent for relapsed multiple myeloma.
    • High-dose therapy with AHSCT is the preferred approach for eligible patients.
    • Allo-HSCT offers a potential immune-based therapeutic option for select patients.